CO6761366A2 - Composiciones farmacéuticas para el tratamiento de glioma maligno - Google Patents

Composiciones farmacéuticas para el tratamiento de glioma maligno

Info

Publication number
CO6761366A2
CO6761366A2 CO13163973A CO13163973A CO6761366A2 CO 6761366 A2 CO6761366 A2 CO 6761366A2 CO 13163973 A CO13163973 A CO 13163973A CO 13163973 A CO13163973 A CO 13163973A CO 6761366 A2 CO6761366 A2 CO 6761366A2
Authority
CO
Colombia
Prior art keywords
treatment
malignant glioma
pharmaceutical compositions
therapeutic agent
radiation therapy
Prior art date
Application number
CO13163973A
Other languages
English (en)
Inventor
Urs Regenass
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45787254&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6761366(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CO6761366A2 publication Critical patent/CO6761366A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere al uso de macitentano en combinación con un agente terapéutico citotóxico (tal como temozolomida o paclitaxel), con radioterapia, o tanto con un agente terapéutico citotóxico como con radioterapia, en el tratamiento de glioma maligno, en particular, glioblastoma multiforme.
CO13163973A 2011-02-04 2013-07-10 Composiciones farmacéuticas para el tratamiento de glioma maligno CO6761366A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2011050494 2011-02-04

Publications (1)

Publication Number Publication Date
CO6761366A2 true CO6761366A2 (es) 2013-09-30

Family

ID=45787254

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13163973A CO6761366A2 (es) 2011-02-04 2013-07-10 Composiciones farmacéuticas para el tratamiento de glioma maligno

Country Status (20)

Country Link
US (1) US20130310407A1 (es)
EP (2) EP2670405B1 (es)
JP (2) JP5642892B2 (es)
KR (1) KR101563069B1 (es)
CN (1) CN103327975A (es)
AR (1) AR085132A1 (es)
AU (1) AU2012213036A1 (es)
BR (1) BR112013019680A2 (es)
CA (1) CA2823994A1 (es)
CL (1) CL2013002193A1 (es)
CO (1) CO6761366A2 (es)
EA (1) EA201391131A1 (es)
IL (1) IL227747A0 (es)
MA (1) MA34952B1 (es)
MX (1) MX2013008798A (es)
SG (1) SG192600A1 (es)
TN (1) TN2013000333A1 (es)
TW (1) TW201309298A (es)
WO (1) WO2012104822A1 (es)
ZA (1) ZA201306613B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY151003A (en) 2005-09-12 2014-03-31 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
EP2464218B1 (en) 2009-08-10 2015-05-27 Board of Regents, The University of Texas System Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
CN103397308A (zh) * 2013-08-01 2013-11-20 光垒光电科技（上海）有限公司 用于mocvd设备的喷淋头
TWI559928B (en) * 2014-08-20 2016-12-01 Academia Sinica Methods for enhancing permeability to blood-brain barrier and uses thereof
KR101701619B1 (ko) 2015-06-26 2017-02-01 건양대학교산학협력단 뇌교종 세포 치료를 위한 테모졸로마이드와 비타민 d가 포함된 조성물
KR102574253B1 (ko) 2020-12-15 2023-09-07 주식회사 시선테라퓨틱스 펩티드 핵산 복합체를 유효성분으로 함유하는 교모세포종 예방 또는 치료용 조성물
CN115317604B (zh) * 2022-08-11 2023-09-22 南京脑科医院 一种靶向胶质瘤的共载放疗增敏阳离子纳米制剂及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155805A0 (en) * 2000-12-18 2003-12-23 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
MY151003A (en) 2005-09-12 2014-03-31 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2008111092A1 (en) * 2007-03-09 2008-09-18 Fresenius Kabi Oncology Limited Crystalline temozolomide monohydrate and process for preparation thereof
RU2494736C2 (ru) * 2008-02-20 2013-10-10 Актелион Фармасьютиклз Лтд Комбинация, включающая паклитаксел, для лечения рака яичников
EP2464218B1 (en) * 2009-08-10 2015-05-27 Board of Regents, The University of Texas System Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent

Also Published As

Publication number Publication date
EP2670405A1 (en) 2013-12-11
EA201391131A1 (ru) 2013-12-30
US20130310407A1 (en) 2013-11-21
MA34952B1 (fr) 2014-03-01
TN2013000333A1 (en) 2015-01-20
AR085132A1 (es) 2013-09-11
JP2014504636A (ja) 2014-02-24
CN103327975A (zh) 2013-09-25
TW201309298A (zh) 2013-03-01
AU2012213036A1 (en) 2013-09-19
BR112013019680A2 (pt) 2016-10-11
KR101563069B1 (ko) 2015-10-23
MX2013008798A (es) 2013-10-17
JP2015057409A (ja) 2015-03-26
NZ615005A (en) 2015-10-30
CA2823994A1 (en) 2012-08-09
IL227747A0 (en) 2013-09-30
CL2013002193A1 (es) 2014-05-09
ZA201306613B (en) 2015-04-29
KR20130118981A (ko) 2013-10-30
SG192600A1 (en) 2013-09-30
EP2965757A1 (en) 2016-01-13
JP5642892B2 (ja) 2014-12-17
WO2012104822A1 (en) 2012-08-09
EP2670405B1 (en) 2015-09-02

Similar Documents

Publication Publication Date Title
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
CO6761366A2 (es) Composiciones farmacéuticas para el tratamiento de glioma maligno
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
NZ749217A (en) Androgen receptor modulator and uses thereof
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CL2011003350A1 (es) Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
UY36075A (es) Derivados de tubulisina
CL2013001009A1 (es) Compuestos heterociclicos fusionados; composicion farmaceutica que los comprende, y uso en el tratamiento de un trastorno proliferativo tal como cancer.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
CL2013001445A1 (es) Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer.

Legal Events

Date Code Title Description
FA Application withdrawn